drugset / Trial / NCT00092456

Consistency Lots Vaccine Study (V260-009)

NCT00092456

Phase 3 Completed 793 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

This study was designed to evaluate consistency in the antibody response to three manufactured lots of an investigational Rotavirus Vaccine.

Timeline

Start
2003-05
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine 6.91e+07 iu Oral
Subject Rotarix Vaccine 8.01e+07 iu Oral
Subject Rotarix Vaccine 8.81e+07 iu Oral

Indications